The issue of drug resistance in gliomas is currently being tackled through multi-targeted therapies, including those aimed at the epidermal growth factor receptor (EGFR) and its downstream signaling pathways, such as PI3K (12). The gene discussed is EGFR; the disease is central nervous system cancer.